Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway

Cholangiocarcinoma is the most common primary malignant tumor of the bile duct. The current standard first-line treatment for advanced or metastatic cholangiocarcinoma is gemcitabine and cisplatin. However, few effective treatment choices exist for refractory cholangiocarcinoma, and additional thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Shin-Yi, Hung, Yi-Ping, Pan, Yi-Ru, Chang, Yu-Chan, Wu, Chiao-En, Hsu, Dennis Shin-Shian, Chang, Peter Mu-Hsin, Lu, Meng-Lun, Huang, Chi-Ying F., Su, Yeu, Hsiao, Michael, Yeh, Chun-Nan, Chen, Ming-Huang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389680/
https://www.ncbi.nlm.nih.gov/pubmed/34440089
http://dx.doi.org/10.3390/biomedicines9080885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389680/
https://www.ncbi.nlm.nih.gov/pubmed/34440089
http://dx.doi.org/10.3390/biomedicines9080885

Ejemplares similares